Astrazeneca P L C (AZN-N)
NYSE:AZN
67.96
1.73
(2.61%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
This summary was created by AI, based on 8 opinions in the last 12 months.
AstraZeneca PLC (AZN) has garnered attention from multiple analysts, indicating a strong potential for growth in the coming years. Analysts highlight a robust drug pipeline and recent positive developments, particularly in oncology and obesity treatment, which are anticipated to significantly drive revenue upwards. Despite facing challenges such as trial failures and investigations in the past, the company has shown resilience with increasing earnings and a promising forecast. With a focus on expanding its R&D initiatives, AstraZeneca is perceived as a valuable investment opportunity with a target price indicating substantial upside potential. Investors are advised to adopt a disciplined approach with recommended stop-loss levels, reflecting the general sentiment of cautious optimism regarding the stock's trajectory.
Our PAST TOP PICK with AZN has triggered its stop at $71. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 1%, when combined with our previous guidance.
They rallied last summer, then faced headwinds last fall when a cancer drug failed to perform in trials and there was an investigation in their large Chinese business. Both problems are clearing now. They have a drug pipeline that should become a great growth story. Trades at 15x PE.
We reiterate AZN as a TOP PICK. Recently reported earnings indicated a 19% increase in earnings and revenues. Management announced positive development on 9 new drugs worth $5 billion in future revenues and a plan to invest over $800 million in Ontario creating 700 jobs. The shares trade at 18x earnings and support a 30% ROE. We recommend trailing up the stop (from $52) to $64, looking to achieve $88 -- upside potential of 21%. Yield 1.4%
(Analysts’ price target is $88.24)The big pharma is developing a GLP-1 weight loss treatment that avoids injections -- a big game changer - and trials are looking good. The stock trades at 32x earnings and supports a 16% ROE. We recommend setting a stop-loss at $52, looking to achieve $88 -- upside potential of 30%. Yield 2.2%
(Analysts’ price target is $88.01)Very strong R&D pipeline, with new products expected. Off recent share price highs, which is a good time to buy. Margins very strong on new products. Expecting earnings to rise in the immediate future. Low double digit EPS @ 16x earnings a very strong value proposition. Will continue to hold for the long term.
Is overlooked in pharma. It boasts an amazing oncology business, including recent positive trial data on phase 2 and 3 lung cancer drugs, which could be breakthroughs. Shares have doubled in the last 5 years and has been climbing since 2016. Last April they delivered a blowout quarter with an earnings beat and a bullish forecast including a 8.5% compound annual growth rate based on doubling multi-billion drugs to 25 by 2030. Also, they are developing obesity drugs.
Astrazeneca P L C(AZN-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 6
Neutral - Hold Signals / Votes : 6
Bearish - Sell Signals / Votes : 6
Total Signals / Votes : 18
Astrazeneca P L C(AZN-N) Frequently Asked Questions
What is Astrazeneca P L C stock symbol?
Astrazeneca P L C is a American stock, trading under the symbol AZN-N on the New York Stock Exchange (AZN). It is usually referred to as NYSE:AZN or AZN-N
Is Astrazeneca P L C a buy or a sell?
In the last year, 18 stock analysts published opinions about AZN-N. 6 analysts recommended to BUY the stock. 6 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Astrazeneca P L C.
Is Astrazeneca P L C a good investment or a top pick?
Astrazeneca P L C was recommended as a Top Pick by on . Read the latest stock experts ratings for Astrazeneca P L C.
Why is Astrazeneca P L C stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Astrazeneca P L C worth watching?
18 stock analysts on Stockchase covered Astrazeneca P L C In the last year. It is a trending stock that is worth watching.
What is Astrazeneca P L C stock price?
On 2025-05-15, Astrazeneca P L C (AZN-N) stock closed at a price of $67.96.
Chart did fine for a while, but then employees in China were under investigation. Results on one drug were interpreted very negatively. Phase 3 trials this year provide a lot of potential catalysts. Great suite of offerings. Not expensive.